	Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancer. Cancer Immunol Immunother Du W, Xiao B, Yang X, Zhan J, Sun H, Yang Y, Fang W, Huang Y, Sun D, Hong S, Zhang L. PMID: 40944717 [PubMed - in process]
	Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited-stage small-cell lung cancer: A retrospective, multi-center, real-world study. Int J Cancer Zhao Z, Rong H, Li M, Xu Y, Tian L, Qiu X, Liao H, Li Y, Wang K, Tang X, Tian P, Zhu D, Zhou Q, Zhang Y. PMID: 40944572 [PubMed - as supplied by publisher]
	EBUS-TBNA for Diagnosis and Staging of Lung Cancer: A Retrospective Regional Analysis Integrating Clinical and Molecular Data (EXPoSURE Score). J Clin Med Andrei GM, Mota, R, Ionovici N, Bunescu M, Zob DL, Biciu, Dumitrescu F, Marcu EA, Cioboat, Olteanu M. PMID: 40943939 [PubMed - in process]
	Immune Checkpoint Inhibition in Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Emerging Mechanisms and Personalized Clinical Strategies. Int J Mol Sci Nasser NJ, Sindhu KK, Nasser L, Shafaee Z, Li J, Resende Salgado L, Li B. PMID: 40943541 [PubMed - in process]
	The Impact of Artificial Intelligence on Lung Cancer Diagnosis and Personalized Treatment. Int J Mol Sci Ayasa Y, Alajrami D, Idkedek M, Tahayneh K, Akar FA. PMID: 40943394 [PubMed - in process]
	Enhanced Lung Cancer Classification Accuracy via Hybrid Sensor Integration and Optimized Fuzzy Logic-Based Electronic Nose. Sensors (Basel) Ozsandikcioglu U, Atasoy A, Guney S. PMID: 40942701 [PubMed - in process]
	Tumor Cell Proportion Assessment in Advanced Non-Squamous Non-Small Cell Lung Cancer Tissue Samples in Real-World Settings in Japan: The ASTRAL Study. Diagnostics (Basel) Hatanaka KC, Nishino K, Yokose T, Tanaka H, Motoi N, Taguchi K, Tamai Y, Hirai T, Yabuki Y, Hatanaka Y. PMID: 40941653 [PubMed - in process]
	Additive Value of EBUS-TBNA for Staging Non-Small Cell Lung Cancer in Patients Evaluated for Stereotactic Body Radiation Therapy. Diagnostics (Basel) Boster JM, Goertzen SM, Sainz PV, Vial MR, Zaveri-Desai JK, Luna LD, Waqar A, Grosu HB, Casal RF, Jimenez CA, Ost DE, Sabath BF, Lin J, Hernandez M, Eapen GA. PMID: 40941624 [PubMed - in process]
	Impact of Intraoperative Lidocaine During Oncologic Lung Resection on Long-Term Outcomes in Primary Lung Cancer: A Post Hoc Analysis of a Randomized Controlled Trial. Cancers (Basel) de la Fuente E, de la Gala F, Hortal J, Simón C, Reyes A, Rancan L, Calvo A, Puig A, Vara E, Bellón JM, Piñeiro P, Garutti I. PMID: 40941021 [PubMed - in process]
	Integrating Artificial Intelligence in Bronchoscopy and Endobronchial Ultrasound (EBUS) for Lung Cancer Diagnosis and Staging: A Comprehensive Review. Cancers (Basel) Winiarski S, Radziszewski M, Wi, Cisek J, W, Plewczy, Górska K, Korczy. PMID: 40940931 [PubMed - in process]
	Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study. Cancers (Basel) Mahmood U, Josephides E, Chitnis M, Skwarski M, Gennatas S, Ghosh S, Spicer J, Karapanagiotou E, Ahmad T, Forster M, Jamal-Hanjani M, Benafif S, Swanton C, Lee SM, Papadatos-Pastos D, Georgiou A, Coupe N. PMID: 40940918 [PubMed - in process]
	Adaptation and Implementation of Self-System Therapy for Older Adults with Advanced Lung Cancer: Pilot Trial Results. Cancers (Basel) Ramos K, Ayaz A, Riley J, Faircloth K, Porter LS, Strauman TJ. PMID: 40940906 [PubMed - in process]
	Cell Death, Molecular Targeted Therapies, and Metabolic Reprogramming in EGFR-Mutant Lung Cancer. Cancers (Basel) Joshi H, Sheikh MS. PMID: 40940888 [PubMed - in process]
	Failure to Rescue and Lung Resections for Lung Cancer: Measuring Quality from the Operation Room to the Intensive Care Unit. Cancers (Basel) Zotos PA, Androutsopoulou V, Scarci M, Minervini F, Cioffi U, Xanthopoulos A, Athanasiou T, Magouliotis DE. PMID: 40940880 [PubMed - in process]
	Effectiveness of health communication intervention to improve knowledge on timeliness to return for annual lung cancer screening: The Larch Trial. Chest Wernli KJ, Anderson ML, Palazzo L, Luce C, Bezman N, Chin M, Gao H, Ralston JD, Rogers K, Su YR, Triplette M, Carter-Bawa L, Vasavada A, Jordan M, West M, Boler S, Green BB. PMID: 40939933 [PubMed - as supplied by publisher]
	Using Bayesian Networks to Predict Urgent Care Visits in Patients Receiving Systemic Therapy for Non-Small Cell Lung Cancer. JCO Clin Cancer Inform Gonzalez BD, Li X, Gudenkauf LM, Pullukkara JJ, Oswald LB, Hoogland AI, Le T, El Naqa I, Saltos AN, Haura EB, Luo Y. PMID: 40939115 [PubMed - in process]
	Machine learning-driven gene expression profiling for lung cancer stage determination. Cancer Biomark Wang Y, Fu K. PMID: 40939066 [PubMed - in process]
	TROP2: as a promising target in lung cancer. Front Oncol Li XX, Chen JL. PMID: 40936682 [PubMed - in process]
	Application of Pharmaceutical Nanotechnologies for Chinese Herbal Medicines in the Treatment of Pulmonary Diseases and Lung Cancer. Int J Nanomedicine Yang X, Niu H, Jiang W, Yu W, Jiang W. PMID: 40936517 [PubMed - in process]
	Anti-tumour effects of perioperative ketamine in lung cancer: a non-randomised, exploratory biomarker study. Br J Anaesth Shishido SN, Shah A, Mason J, Scarpa JR, Amar D, Desiderio D, Pedoto A, De Camilli A, Guaran C, Jackson JC, Lewis A, Zanone M, Nystrom L, Fischer GW, Jones DR, Gulati A, Scher H, Barnett E, Mincer JS, Kuhn P. PMID: 40935722 [PubMed - as supplied by publisher]

Articles 1 - 20 / 150010

Page 1 of 7501



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy